Sarepta Therapeutics, Inc. (SRPT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.83-3.14 (-5.15%)
At close: 4:00 PM EDT
People also watch:
ACADCLVSCLDXPTCTICPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open60.61
Prev Close60.97
Bid57.90 x 100
Ask58.40 x 300
Day's Range57.24 - 60.70
52wk Range8.00 - 61.60
1y Target EstN/A
Market Cap2.77B
P/E Ratio (ttm)-10.80
Beta1.71
Volume9,345,828
Avg Vol (3m)3,938,942
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.comyesterday

    [$$] Sarepta Still Has Upside

    Review | Preview Sarepta Therapeutics quickly emerged as one of biotechnology’s hottest stories last week after the Food and Drug Administration Monday approved the company’s drug for Duchenne muscular dystrophy, a fatal, inherited muscle-wasting disease affecting boys that until now has had no approved treatments. The FDA decision came after a tumultuous multi-year approval process that ultimately saw the head of the FDA’s drug-approval division, Janet Woodcock, overrule FDA staff and back the drug, which has strong support in the DMD community where it is widely viewed as effective in slowing the progression of the disease. After what industry observers said was an unprecedented internal dispute, FDA commissioner Robert Califf backed Woodcock, who is being hailed as a hero by many families of boys suffering from DMD.

  • Investopediayesterday

    Sarpeta Approval Challenged by FDA (SRPT)

    Will Sarepta’s approval be revoked following the FDA commissioner’s call for retraction of the company's 2013 study?

  • Investopediayesterday

    Sarpeta Raises Offering After FDA Approval (SRPT)

    Sarepta has increased the amount of capital to be raised to $300 million in a public offering